email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2638-5945

Open Access Journal of Oncology and Medicine

Mini Review(ISSN: 2638-5945)

Adjuvant Therapy in High-Risk Cutaneous Squamous Cell Carcinoma: New Challenges

Volume 4 - Issue 1

GV Schiappacasse123*

  • Author Information Open or Close
    • 1Chief Physician, Oncology Department, Clinical Hospital, Chile
    • 2Oncology Department, Bupa Reñaca Clinic, Chile
    • 3Oncology Department, Ciudad del Mar Clinic, Chile

    *Corresponding author: GV Schiappacasse, Chief Physician, Oncology Department, Clinical Hospital, Chile

Received: August 20, 2020;   Published: September 11, 2020

DOI: 10.32474/OAJOM.2020.04.000179

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Non-melanoma skin cancer is the most common tumor in the world; and cutaneous squamous cell carcinoma (cSCC) accounts for 20% of cases. It has a very good prognosis, except for the high-risk group. Studies of this group, despite its low frequency (5%), are extremely important because the cancer has a high risk of relapse and development of locoregional and distant metastasis. And this is directly correlated with higher and significant mortality. Therefore, since there is limited data on current adjuvant therapies after surgery, or the therapies are not beneficial, we propose to investigate the benefit of anti-PD-1 and epidermal growth factor receptor (EGFR) inhibitors as adjuvant therapies in high-risk cSCC as supported by translational research and based on the available evidence.

Keywords: Cutaneous Squamous Cell Carcinoma; High-Risk; Adjuvant; Immunotherapy; EGFR Inhibitors

Abstract| Introduction| Risk Factors| Histological characteristics| State of the Art in High-Risk cSCC| Adjuvant Therapies| New Perspectives for Adjuvant Therapies in High- Risk cSCC| What is the Optimal Duration of Adjuvant Therapy?| Conclusion| References|